LETTER TO THE EDITOR

Comment on “Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?”

Alain Munafo1 · Axel Krebs-Brown2 · Sumedh Gaikwad2 · Bogumila Urgatz2 · Claire Castello-Bridoux3

Published online: 12 June 2019
© The Author(s) 2019

Dear Editor,

Retrospective analyses of data generated in clinical trials can provide valuable contributions to drug development and stimulate innovation and progress. Concordet et al. recently published an opinion paper that questioned the use of average bioequivalence by health authorities for evaluation of a drug like Levothyrox® [1]. They propose instead a “conceptual framework of individual bioequivalence”. The concept of individual bioequivalence has been a topic of intense debate, but no regulatory agency has endorsed a general framework for individual bioequivalence and there are no reference ranges, guidance or directives on its use. This opinion paper is built on a post-hoc analysis of data from a clinical study (EudraCT No: 2013-000274-29) that had demonstrated bioequivalence between the new and old formulations of levothyroxine. The introduction of the new formulation has elicited numerous reports of adverse events in France, which led the authors to investigate the notion of “switchability”, using an individual exposure ratio (IER).

The authors acknowledge that the study and its analysis were performed according to applicable guidelines in France, Europe and the USA, yet argue for an individual approach and lean towards a possible subject-by-formulation interaction explaining the outcome of their analysis. We propose an alternative perspective to the hypotheses brought by Concordet et al.

The authors calculated the IER for the 204 subjects who contributed to the primary analysis in the trial and observed that “50% […] were actually outside the a priori bioequivalence range”. No such established bioequivalence range exists for individual estimates. In addition, the spread of IER estimates may be explained largely by factors other than a putative “subject-by-formulation” interaction, as speculated. Bioequivalence in this study was achieved where the 90% confidence intervals around the point estimate for geometric mean ratios of key pharmacokinetic parameters lay between 0.9 and 1.11. This was consistent with the narrow therapeutic index of levothyroxine, in comparison to the “usual” range of 0.8–1.25. This is not a validated range for ratios calculated for each individual, and there is no scientific rationale for categorising individual responses according to population boundaries.

Furthermore, the study was not designed to evaluate subject-by-formulation interaction, in accordance with applicable guidelines. It is known that there can be a link between the variance term measuring subject-by-formulation interaction and the spreading of IER values. Although we cannot exclude that the subject-by-formulation might contribute to the widening of the distribution of the IER, we propose an alternative explanation.

The exposure metrics for levothyroxine were assessed with or without adjustment for the baseline thyroxine (T4) level. In the reported clinical study in healthy subjects, endogenous T4, i.e., before levothyroxine treatment, represented about two thirds of the total exposure to T4 (area under the concentration–time curve) after treatment. Each concentration measurement bears an analytical error (assay precision), and we performed simulations to investigate the propagation of errors associated with the calculation of the IER, on unadjusted and adjusted concentrations. We simulated a cross-over study in 10,000 subjects, receiving levothyroxine twice, and assuming that the only difference in subjects’ pharmacokinetic profiles was due to bioanalytical error. The pharmacokinetic profiles were simulated

This comment refers to the article available at https://doi.org/10.1007/s40262-019-00747-3.

Claire Castello-Bridoux claire.castello-bridoux@merckgroup.com

1 Merck Institute for Pharmacometrics—an affiliate of Merck KGaA, Darmstadt, Germany, Lausanne, Switzerland
2 Merck Healthcare KGaA, Darmstadt, Germany
3 Merck Santé s.a.s—an affiliate of Merck KGaA, Darmstadt, Germany, Lyon, France

△ Adis
assuming identical and independent lognormal distributions of individual concentrations, with the means based on the geometric mean profiles seen in the study, and assuming a constant standard deviation of 0.10 (corresponding to a coefficient of variation of 10%, which is very comparable to the precision of the bioanalytical method). From these simulated concentrations, we derived the IER on both the baseline-adjusted and the unadjusted area under the concentration–time curve, calculated using the linear trapezoidal rule as also employed by Concordet et al. The results are displayed in Table 1 and Fig. 1.

Table 1 Summary outcome of the individual exposure ratio calculated from 10,000 pairs of simulated total thyroxine levels without and with baseline subtraction

|                      | Unadjusted | Adjusted |
|----------------------|------------|----------|
| Mean (SD)            | 1.00 (0.0527) | 1.03 (0.268) |
| Proportion outside 0.8–1.25 | 0.01%    | 36.3%    |
| Proportion outside 0.9–1.11 | 4.75%    | 66.0%    |

SD standard deviation

Fig. 1 Distribution of individual exposure ratio (area under the curve test/area under the curve reference) obtained with unadjusted thyroxine (left panel) and baseline-adjusted thyroxine (right panel) simulated plasma levels. Red and blue vertical dotted lines represent ranges of 0.8–1.25 and 0.9–1.11, respectively. Pharmacokinetic profiles for 10,000 subjects were simulated over the course of 72 h, assuming a bioanalytical error of 10%, no difference in pharmacokinetic profiles under both formulations and the absence of a subject-by-formulation interaction

Thus, the distribution of the IER can widen substantially, irrespective of the magnitude of a putative subject-by-formulation interaction. This is owing to the (proportionally large) baseline subtraction, and computation of the ratio from the smaller adjusted area under the concentration–time curves. This inflated the variability and probably explains the statement that more than 50% of the healthy volunteers’ IER fell outside a 0.9–1.11 range. Accordingly, this spreading may be artefactual and largely the result of inflation of the analytical (im)precision due to the calculation.

The authors also question the appropriateness of using healthy volunteers to assess bioequivalence for levothyroxine. The use of healthy volunteers in bioequivalence trials allows a more straightforward comparison of pharmacokinetics, offers fewer opportunities for confounding effects, is typically more sensitive to any changes in formulations, especially after single-dose administration, and is considered the gold standard for these studies. Healthy euthyroid subjects show less physiological variation than patients, with little, if any, impact on thyroid function of variables such as physical training, body habitus, posture, immobilisation, exercise, ambulatory status or geographic environment. If patients were enrolled in this study, other medicines, organ dysfunction or even the disease itself could vary between the time of administrations of both formulations to the individual subjects and confuse the findings.

In conclusion, we believe that the findings of Concordet et al. can be explained largely by the propagation of experimental errors implied by the calculation, rather than any subject-by-formulation interaction. We also believe that the model of single-dose bioequivalence assessment in healthy volunteers, be it with or without baseline subtraction, provides the most stringent test conditions to identify any possible difference between formulations. Real-world data from other countries where the new formulation has been launched show no increased safety reporting and no impact on the benefit-risk balance of the product and hence, does not corroborate the authors’ conjecture of non-bioequivalence for more than 50% of the population.
Comment on “Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?”

Compliance with Ethical Standards

Funding  No sources of funding were used in the preparation of this letter.

Conflict of Interest  Alain Munafo, Axel Krebs-Brown, Sumedh Gaikwad, Bogumila Urgatz and Claire Castello-Bridoux are employees of Merck KGaA, Darmstadt, Germany, or of one of its affiliates.

Open Access  This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran A, Toutain P-L. Levothyrox® new and old formulations: are they switchable for millions of patients? Clin Pharmacokinet. 2019. https://doi.org/10.1007/s40262-019-00747-3 (Epub ahead of print).
2. Adkin DA, Davis SS, Sparrow RA, Huckle PD, Phillips AJ, Wilding IR. The effect of different concentrations of mannitol in solution on small intestinal transit: implications for drug absorption. Pharm Res. 1995;12:393–6.